secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAXOR CORP (DXR)
CIK:        0000027367
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001641172-25-022513
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer
----------------------------------------------------------------------

- FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.
- Device provides results 3x faster, weighs 7 lbs, delivers lab-grade precision.
- Clinical data: BVA-guided care reduced heart failure mortality by 86% (p<0.001), ICU mortality by 66%.
- Over 75,000 tests shipped; developed under U.S. Army/DHA contract.
- Management expects high demand driven by speed, simplicity, precision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/27367/000164117225022513/0001641172-25-022513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/27367/000164117225022513/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer